Literature DB >> 29602065

Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.

Gelareh Shokri1, Shaghayegh Doudi2, Mehrnoosh Fathi-Roudsari3, Fatemeh Kouhkan4, Mohammad-Hossein Sanati2.   

Abstract

Epigenetic modifications play an important role in initiation and progression of cancers including acute myeloid leukemia. Among different epigenetic modifiers, lysine specific demethylases have been noticed as potential therapeutic targets. KDM5 family of histone demethylases which removes methyl marks from lysine residues of H3, are frequently found in the promoter region of transcriptionally active genes resulting in repression of expression. Here we have compared the effects of KDM5A and KDM5B downregulation on HL-60 cell line behavior. KDM5A/5B knockdown resulted in lower viability of HL-60 cells in addition to modified cell cycle distribution and sub-G1 accumulation. Induction of apoptosis was observed in both knockdown cells. But in spite of similarity in their role, downregulation of KDM5A showed more efficient anti-leukemic effects in comparison to KDM5B. Cells showed higher accumulation in sub-G1 and apoptosis occurred significantly higher and also earlier after KDM5A reduction. Expression analysis confirmed almost 5 and 4 fold increased expression for bax and caspase-3 after downregulation of KDM5A in comparison to KDM5B. Due to the present study we propose KDM5A as a potential target for therapeutic aspects of acute myeloid leukemia although further investigations are needed.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Acute myeloid leukemia; Epigenetic modification; Histone methylation; KDM5A; KDM5B

Mesh:

Substances:

Year:  2018        PMID: 29602065     DOI: 10.1016/j.leukres.2018.02.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.

Authors:  John R Horton; Clayton B Woodcock; Qin Chen; Xu Liu; Xing Zhang; John Shanks; Ganesha Rai; Bryan T Mott; Daniel J Jansen; Stephen C Kales; Mark J Henderson; Matthew Cyr; Katherine Pohida; Xin Hu; Pranav Shah; Xin Xu; Ajit Jadhav; David J Maloney; Matthew D Hall; Anton Simeonov; Haian Fu; Paula M Vertino; Xiaodong Cheng
Journal:  J Med Chem       Date:  2018-11-15       Impact factor: 7.446

2.  Lysine demethylase 5A promotes prostate adenocarcinoma progression by suppressing microRNA-330-3p expression and activating the COPB2/PI3K/AKT axis in an ETS1-dependent manner.

Authors:  Yuanyuan Mi; Lifeng Zhang; Chuanyu Sun; Yanyan Feng; Jian Sun; Jun Wang; Dongjie Yang; Xiaowei Qi; Hongyuan Wan; Guowei Xia; Sheng Wu; Lijie Zhu
Journal:  J Cell Commun Signal       Date:  2022-05-18       Impact factor: 5.782

3.  KDM5A suppresses PML-RARα target gene expression and APL differentiation through repressing H3K4me2.

Authors:  Siyuan Xu; Siqing Wang; Shenghui Xing; Dingdang Yu; Bowen Rong; Hai Gao; Mengyao Sheng; Yun Tan; Xiaojian Sun; Kankan Wang; Kai Xue; Zhennan Shi; Fei Lan
Journal:  Blood Adv       Date:  2021-09-14

4.  Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells.

Authors:  Jacopo Albanesi; Nelida Ines Noguera; Cristina Banella; Tommaso Colangelo; Elisabetta De Marinis; Stefano Leone; Orazio Palumbo; Maria Teresa Voso; Paolo Ascenzi; Clara Nervi; Fabrizio Bianchi; Alessandra di Masi
Journal:  Cells       Date:  2020-11-05       Impact factor: 6.600

Review 5.  JMJD family proteins in cancer and inflammation.

Authors:  Wang Manni; Xue Jianxin; Hong Weiqi; Chen Siyuan; Shi Huashan
Journal:  Signal Transduct Target Ther       Date:  2022-09-01

6.  Evidence of Omics, Immune Infiltration, and Pharmacogenomic for SENP1 in the Pan-Cancer Cohort.

Authors:  Somayye Taghvaei; Farzaneh Sabouni; Zarrin Minuchehr
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

7.  Increased Expression of Lysine-Specific Demethylase 5B (KDM5B) Promotes Tumor Cell Growth in Hep3B Cells and is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma.

Authors:  Jian Gong; Shuyuan Yan; Hui Yu; Wenhua Zhang; Di Zhang
Journal:  Med Sci Monit       Date:  2018-10-24

Review 8.  Epigenetic Targeting of Glioblastoma.

Authors:  Massimo Romani; Maria Pia Pistillo; Barbara Banelli
Journal:  Front Oncol       Date:  2018-10-16       Impact factor: 6.244

Review 9.  Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate.

Authors:  Andrew B Das; Carlos C Smith-Díaz; Margreet C M Vissers
Journal:  Haematologica       Date:  2021-01-01       Impact factor: 9.941

10.  KDM5A and KDM5B histone-demethylases contribute to HU-induced replication stress response and tolerance.

Authors:  Solenne Gaillard; Virginie Charasson; Cyril Ribeyre; Kader Salifou; Marie-Jeanne Pillaire; Jean-Sebastien Hoffmann; Angelos Constantinou; Didier Trouche; Marie Vandromme
Journal:  Biol Open       Date:  2021-05-26       Impact factor: 2.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.